Pharmacological suppression of the kallikrein kinin system with KVD900: An orally available plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema.

Edward J DuckworthNivetha MurugesanLily LiLouise J RushbrookeDaniel K LeeGian Marco De DonatisAndreas MaetzelChristopher M YeaSally L Hampton Edward P Feener

Published in: Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology (2022)

KVD900 is a fast-acting oral PKa inhibitor that rapidly inhibits PKa activity, kallikrein kinin system activation and HK cleavage in plasma. On-demand administration of KVD900 may provide an opportunity to halt the generation of bradykinin and reverse HAE attacks.

Keyphrases

angiotensin converting enzyme
dna binding
replacement therapy
transcription factor
high glucose
angiotensin ii